IL-4 and IL-13 were upregulated in ILC2s cells, particularly in PD-1high ILC2s in NSCLC patients, and boosted M2-like macrophage polarization, warranting clinical trials of Dupilumab in NSCLC patients in the future. The gene discussed is IL4; the disease is non-small cell lung carcinoma.